Laboratory confirmed cases of pertussis (England): annual report for 2018

Health Protection Report
Volume 13 Number 14
26 April 2019
Laboratory confirmed cases of pertussis (England): annual report for 2018

In England, there were 2947 laboratory confirmed cases of pertussis (culture, PCR, serology or oral fluid) reported to the Public Health England pertussis enhanced surveillance programme in 2018. Pertussis is a cyclical disease, with increases occurring every 3-4 years, with pertussis activity usually peaking each year in quarter three. The 2947 confirmed cases in England in 2018 were 32% lower than the 4341 reported in 2017 (Figure 1). Almost a third (31%; 907/2947) of all confirmed cases in England in 2018 were reported in the third quarter (July to September) (table1).

A national outbreak of pertussis [1] was declared by the HPA in April 2012 and, as a response to the ongoing outbreak, the Department of Health (DH) introduced a temporary immunisation programme for pregnant women from October 2012 [2]. In June 2014 the Joint Committee on Vaccination and Immunisation (JCVI) advised that the programme should continue for a further five years [3] based on UK evidence of impact, high effectiveness and safety and continuing high levels of disease [4,5,6,7]. From 1 April 2016 the recommended gestational age for vaccination was revised to between 20-32 weeks but can be given as early as 16 weeks [3].

The national incidence for all age groups, based on laboratory confirmations in England and 2017 population estimates [10], was 5 per 100,000 in 2018 compared to 8/100,00 in the previous year and 11/100,000 in 2016; it reached 18/100,000 in 2012 (epidemic peak year). Prior to the major peak in 2012, incidence ranged between 0.4/100,000 to 2/100,000 (figure 2).

Laboratory confirmed pertussis cases in infants aged under one year, were 46% lower in 2018 (92 cases) than in 2017 (169 cases). This compares with 508 confirmed cases reported in 2012. The 92 infant cases in 2018 were the lowest number of confirmed cases reported since 2010.
There has been a decline in pertussis incidence in infants under 3 months of age since the introduction of the maternal vaccination programme, from 234/100,000 in 2012 to 93/100,000 in 2016 and 30/100,000 in 2018 (figure 2). The number of confirmed cases in infants <3 months was 49 in 2018, the lowest number of confirmed cases since the introduction of enhanced surveillance in 1994. Cases in this age group were 57% lower in 2018 compared to 2017 (115 cases). Incidence does however remain highest in infants under 3 months who are at most risk of severe disease and too young to be fully vaccinated.

Cases in older infants have also remained low since the 2012 epidemic peak when there were 74 cases (43/100,000) in infants aged 3-5 months. There were 26 cases (16/100,000) in this age group in 2018 compared to 37 (23/100,000) in 2017. In the 2016 cyclical peak, confirmed cases aged 6-11 months were higher (34 cases, 10/100,000) than in any year since the introduction of enhanced surveillance. In both 2017 and 2018, the incidence in this age group was 5/100,000 with 17 cases reported each year. These low numbers are consistent with protection from primary vaccination offered at 2, 3 and 4 months of age.

In all children aged 1 year and older numbers of confirmed cases were lower in 2018 than in 2017 (30% lower in 5-9 year olds and 22% lower in 10-14 year olds). The only exception was those aged 1-4 years where cases in 2018 (86 cases) were 15% higher than those confirmed in 2017 (75 cases). Ascertainment in those aged 5 to <17 years has improved with availability of oral fluid testing since 2013. From 1 May 2018, the availability of oral fluid testing was extended to all children aged 2 to <17 years which may underpin the increase observed in the 1-4 year age group in 2018.

Whilst most (79%; 2342/2947) (table 2) laboratory confirmed cases in England in 2018 occurred in individuals aged 15 years and older, total numbers in 2018 (2342 cases) were 34% lower than in 2017 (3530 cases).
In England, 14 deaths were reported in infants with confirmed pertussis in the 2012 epidemic peak year. Following the introduction of pertussis vaccination in pregnancy there have been 19 further deaths in babies with confirmed pertussis including one death reported in 2018. All the deaths in 2012 and those that have occurred following the introduction of the maternal programme were too young to be fully protected by infant vaccination. Only two of the infants born after the introduction of the maternal programme had a mother who had been vaccinated during pregnancy. In both cases the vaccination was too close to delivery to confer optimal passive protection in the infant.

The most recent PHE figures report that the proportion of mothers due to give birth between January 2018 and December 2018 who had been immunised with a pertussis containing vaccine in pregnancy in England ranged from a monthly average of 67.6% (July) to 72.9% (January, December) [8], lower than in 2017 but continuing at the higher levels seen since April 2016 when changes to the way coverage data are extracted from GP systems and extended gestational eligibility criteria for the vaccine came into effect [9,3]. This drop could represent a genuine decrease, or reflects an increase in vaccines administered in maternity settings, which is poorly recorded in primary care records.

The surveillance data in young infants following the introduction of a programme to immunise pregnant women demonstrate that, despite high levels of circulating pertussis, a relatively low incidence has been maintained in infants being targeted by the programme, even during the expected seasonal increases. It is important to be aware, however, that raised levels of pertussis persist in all age groups other than infants. Women should, therefore, continue to be encouraged to be immunised against pertussis at the optimal time during pregnancy in order to protect their babies from birth. It is important that information on vaccines administered in pregnancy is transferred to primary care and that records held in primary care are updated accordingly. The advice to offer vaccination earlier in pregnancy should lead to more opportunities for pregnant women to be vaccinated and to have their vaccine status checked.
Figure 1. Total number of laboratory confirmed pertussis cases per evaluation quarter in England: 2009 to 2018

Table 1. Laboratory confirmed cases of pertussis by quarter and test method* in England: 2018

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Culture</th>
<th>PCR</th>
<th>Serology</th>
<th>Oral fluid only</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan - Mar</td>
<td>10</td>
<td>22</td>
<td>587</td>
<td>28</td>
<td>647</td>
</tr>
<tr>
<td>Apr - Jun</td>
<td>12</td>
<td>34</td>
<td>594</td>
<td>39</td>
<td>679</td>
</tr>
<tr>
<td>Jul - Sep</td>
<td>18</td>
<td>51</td>
<td>787</td>
<td>51</td>
<td>907</td>
</tr>
<tr>
<td>Oct - Dec</td>
<td>6</td>
<td>29</td>
<td>642</td>
<td>37</td>
<td>714</td>
</tr>
<tr>
<td>Total</td>
<td>46</td>
<td>136</td>
<td>2610</td>
<td>155</td>
<td>2947</td>
</tr>
</tbody>
</table>

* Culture confirmed cases may additionally have tested positive by any other method, PCR confirmed cases may have additionally tested positive by serology or OF and serology confirmed cases may also have been confirmed by OF. Cases are only represented once in the table. Submission of all presumptive *B. pertussis* isolates is encouraged for confirmation of identity and to allow further characterisation for epidemiological purposes.
Figure 2. Incidence of laboratory confirmed pertussis cases by age group in England: 1998-2018

Table 2. Age distribution of laboratory confirmed cases of pertussis by test method* in England: 2018

<table>
<thead>
<tr>
<th>Age group</th>
<th>Culture</th>
<th>PCR</th>
<th>Serology</th>
<th>Oral fluid only</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;3 months</td>
<td>15</td>
<td>34</td>
<td>0</td>
<td>0</td>
<td>49</td>
</tr>
<tr>
<td>3-5 months</td>
<td>4</td>
<td>21</td>
<td>1</td>
<td>0</td>
<td>26</td>
</tr>
<tr>
<td>6-11 months</td>
<td>5</td>
<td>9</td>
<td>3</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>1-4 years</td>
<td>5</td>
<td>23</td>
<td>40</td>
<td>18</td>
<td>86</td>
</tr>
<tr>
<td>5-9 years</td>
<td>2</td>
<td>7</td>
<td>81</td>
<td>49</td>
<td>139</td>
</tr>
<tr>
<td>10-14 years</td>
<td>3</td>
<td>2</td>
<td>216</td>
<td>67</td>
<td>288</td>
</tr>
<tr>
<td>15+ years</td>
<td>12</td>
<td>40</td>
<td>2269</td>
<td>21</td>
<td>2342</td>
</tr>
<tr>
<td>Total</td>
<td>46</td>
<td>136</td>
<td>2610</td>
<td>155</td>
<td>2947</td>
</tr>
</tbody>
</table>

* Culture confirmed cases may additionally have tested positive by any other method. PCR confirmed cases may have additionally tested positive by serology or OF and serology confirmed cases may also have been confirmed by OF. Cases are only represented once in the table. Submission of all presumptive B. pertussis isolates is encouraged for confirmation of identity and to allow further characterisation for epidemiological purposes.
References

1. HPR 6(15), 13 April 2012:


3. JCVI minutes: https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation#minutes


8. HPR 13(14), 26 April 2019


10. Office for National Statistics:

About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner.

About Health Protection Report

Health Protection Report is a national public health bulletin for England and Wales, published by Public Health England. It is PHE’s principal channel for the dissemination of laboratory data relating to pathogens and infections/communicable diseases of public health significance and of reports on outbreaks, incidents and ongoing investigations.

Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG
Tel: 020 7654 8000   www.gov.uk/phe
Twitter: @PHE_uk   Facebook: www.facebook.com/PublicHealthEngland
Queries relating to this document should be directed to: Immunisation, Hepatitis and Blood Safety Department, National Infection Service, PHE Colindale, 61 Colindale Avenue, London NW9 5EQ.
immunisation@phe.gov.uk

© Crown copyright 2019
You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published: April 2019
PHE publications gateway number: 2018810
PHE supports the UN Sustainable Development Goals